The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models

Katie E. Hebron(Vanderbilt University), Marielle E. Yohe(National Cancer Center), Priya Shankarappa(Center for Cancer Research), Haiyan Lei(National Cancer Institute), Javed Khan(Kent State University), Cody J. Peer(National Institutes of Health), Matthew D. Hall(National Institutes of Health), Frederic G. Barr(National Institutes of Health), William J.E. Frye(Center for Cancer Research), Stacey Stauffer(Center for Cancer Research), Kristine A. Isanogle(Leidos (United States)), Xiaoling Luo(National Cancer Institute), Roberta Smith(Leidos (United States)), Robert L. Kortum(Uniformed Services University of the Health Sciences), Robert W. Robey(National Institutes of Health), Noémi Kedei(Center for Cancer Research), Nancy E. Sealover(Uniformed Services University of the Health Sciences), Angela Kim(Center for Cancer Research), David J. Liewehr(Center for Cancer Research), Xiaolin Wan(National Cancer Institute), Wenyue Sun(Greater Baltimore Medical Center), Elijah F. Edmondson(Leidos (United States)), Simone Difilippantonio(Leidos (United States)), Amy James(Leidos (United States)), Christina M. Robinson(Northwestern University), Jacob S. Roth(National Institutes of Health), William D. Figg(National Cancer Institute), Parirokh Awasthi(Science Applications International Corporation (United States)), Olivia L. Perkins(Center for Cancer Research), Angelina V. Vaseva(The University of Texas at San Antonio Health Science Center), Donna Butcher(Frederick National Laboratory for Cancer Research), Jack F. Shern(National Institutes of Health), Lu Chen(Chengdu University of Traditional Chinese Medicine), Jin‐Qiu Chen(National Institutes of Health)
Clinical Cancer Research
November 2, 2022
Cited by 21


Related Papers